On January 12, 2026, BioMarin Pharmaceutical Inc. announced the appointment of Arpit Davé as Executive Vice President, Chief Digital and Information Officer. Reporting directly to President and CEO Alexander Hardy, Mr. Davé joins the San Rafael–based biotech firm with more than 20 years of experience in information technology and artificial intelligence within the biopharmaceutical sector. His remit includes reimagining and executing the company’s enterprise technology strategy, data science initiatives and digital transformation efforts to generate value for patients, employees and shareholders.

Prior to joining BioMarin, Mr. Davé spent seven and a half years at Amgen, leading cross-functional teams focused on digital innovation and artificial intelligence to drive operational efficiency and competitive positioning. Earlier in his career, he held leadership roles at Bristol Myers Squibb and Merck, where he oversaw CIO functions and data science projects supporting research and development. He holds an M.S. in Industrial Engineering from the University of Texas and a B.S. in Mechanical Engineering from S.P. University in India.

BioMarin, founded in 1997 and known for eight commercial therapies addressing genetically defined conditions, seeks to leverage Mr. Davé’s expertise to accelerate drug discovery and streamline manufacturing and commercialization processes. CEO Alexander Hardy emphasized that deploying advanced analytics and AI tools will differentiate BioMarin’s operations across R&D and production, potentially shortening time-to-market for category-defining therapies. Investors may view this leadership addition as a reinforcement of BioMarin’s commitment to digital excellence in the rare disease space.